About this Research Topic
Neuroimaging stands at the forefront of modern neuroscience, particularly in the study of neurodegenerative diseases. Key pathological features, specifically TDP-43 proteinopathy and tauopathy, are central to disorders such as Alzheimer’s disease, frontotemporal lobar degeneration (FTLD), and amyotrophic lateral sclerosis (ALS). These proteinopathies are implicated in a diverse range of neurodegenerative conditions, including limbic predominant age-related TDP-43 encephalopathy (LATE) and progressive supranuclear palsy (PSP). Recent advancements in imaging technologies, including MRI and PET scans, have significantly enhanced the detection and understanding of these proteins in the human brain, offering new insights into their role and progression in disease states.
This Research Topic aims to push the boundaries of early diagnosis and ongoing monitoring of neurodegenerative diseases through the lens of neuroimaging. The goal is to refine and validate novel imaging biomarkers for TDP-43 and tau proteinopathies, facilitating better translational successes and clinical application. By developing more reliable diagnostic tools, this research seeks to overcome current challenges such as the variability of imaging markers across populations and the limited translation of preclinical findings into clinical practice.
In pursuit of enhancing diagnostic techniques and therapeutic monitoring, the scope of this research topic is broad yet focused. To further enrich the research base, we encourage contributions that:
• Standardize neuroimaging biomarkers across diverse demographic and genetic backgrounds
• Enhance the translational pipeline from laboratory settings to real-world clinical applications.
Furthermore, contributions are encouraged from multidisciplinary fields within neuroscience, focusing on studies that:
• Utilize novel neuroimaging techniques to elucidate the structural and functional impacts of TDP-43 and tau in neurodegenerative diseases
• Explore the potential of emerging neuroimaging technologies to detect early pathological changes before clinical symptoms manifest.
This topic is not only a call for rigorous scientific inquiry but also a platform for innovation in the fight against neurodegeneration.
To gather further insights in this evolving field, we welcome articles addressing, but not limited to, the following themes:
• Development of advanced imaging modalities that improve the specificity and sensitivity of TDP-43 and tau detection.
• Innovative applications of machine learning and artificial intelligence in neuroimaging analysis for early diagnosis.
• Exploration of novel contrast agents that enhance imaging of these proteinopathies.
• Integration of neuroimaging with other biomarker modalities for a comprehensive understanding of disease mechanisms.
• Investigations into the role of neuroimaging in monitoring related treatment efficacy and disease progression.
• Studies highlighting the use of neuroimaging in diverse populations to identify variations in disease manifestation and progression.
This call for contributions emphasizes the importance of new methods and cutting-edge applications of existing methods in advancing our understanding and management of neurodegenerative diseases.
This Research Topic aims to push the boundaries of early diagnosis and ongoing monitoring of neurodegenerative diseases through the lens of neuroimaging. The goal is to refine and validate novel imaging biomarkers for TDP-43 and tau proteinopathies, facilitating better translational successes and clinical application. By developing more reliable diagnostic tools, this research seeks to overcome current challenges such as the variability of imaging markers across populations and the limited translation of preclinical findings into clinical practice.
In pursuit of enhancing diagnostic techniques and therapeutic monitoring, the scope of this research topic is broad yet focused. To further enrich the research base, we encourage contributions that:
• Standardize neuroimaging biomarkers across diverse demographic and genetic backgrounds
• Enhance the translational pipeline from laboratory settings to real-world clinical applications.
Furthermore, contributions are encouraged from multidisciplinary fields within neuroscience, focusing on studies that:
• Utilize novel neuroimaging techniques to elucidate the structural and functional impacts of TDP-43 and tau in neurodegenerative diseases
• Explore the potential of emerging neuroimaging technologies to detect early pathological changes before clinical symptoms manifest.
This topic is not only a call for rigorous scientific inquiry but also a platform for innovation in the fight against neurodegeneration.
To gather further insights in this evolving field, we welcome articles addressing, but not limited to, the following themes:
• Development of advanced imaging modalities that improve the specificity and sensitivity of TDP-43 and tau detection.
• Innovative applications of machine learning and artificial intelligence in neuroimaging analysis for early diagnosis.
• Exploration of novel contrast agents that enhance imaging of these proteinopathies.
• Integration of neuroimaging with other biomarker modalities for a comprehensive understanding of disease mechanisms.
• Investigations into the role of neuroimaging in monitoring related treatment efficacy and disease progression.
• Studies highlighting the use of neuroimaging in diverse populations to identify variations in disease manifestation and progression.
This call for contributions emphasizes the importance of new methods and cutting-edge applications of existing methods in advancing our understanding and management of neurodegenerative diseases.
Keywords: TDP-43 proteinopathy, neurodegenerative disease, MRI, PET, neruroimaging, neurodegeneration, Alzheimer’s disease
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
